- 1. leucine
- [essential branched-chain amino acid important for hemoglobin formation. ( CSP )] (UMLS (CSP) C0023401) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance =Amino Acids, Branched-Chain;
Amino Acids, Essential;
primary aminoacid;
Inactive Ingredient Preparations =LEUCINE 270 MG;
LEUCINE 1.38 GM/100ML;
LEUCINE 0.77 GM;
LEUCINE 1.37 GM;
LEUCINE 10 MG/ML;
LEUCINE 10.4 MG/ML;
LEUCINE 108 MG/GM;
LEUCINE 12 MG/ML;
LEUCINE 15.76 MG/ML;
LEUCINE 217 MG;
LEUCINE 3.5 MG/ML;
LEUCINE 329 MG/100ML;
LEUCINE 330 MG/100ML;
LEUCINE 340 MG;
LEUCINE 340 MG/100ML;
LEUCINE 4.25 MG/ML;
LEUCINE 5 MG/ML;
LEUCINE 526 MG;
LEUCINE 6.6 MG/ML;
LEUCINE 660 MG;
LEUCINE 660 MG/100ML;
LEUCINE 7 MG/ML;
LEUCINE 7.7 MG;
LEUCINE 7.9 MG/ML;
LEUCINE 71.5 MG;
LEUCINE 726 MG/100ML;
LEUCINE 730 MG/100ML;
LEUCINE 770 MG/100ML;
LEUCINE 8.1 MG/ML;
LEUCINE 8.5 MG/ML;
LEUCINE 840 MG/100ML;
LEUCINE 910 MG/100ML | - 45. leukocyte preservation
- [ ] (UMLS (CSP) C0598022) =Laboratory Procedure ;
|
- 2. Leucine Rich Repeat Containing 17 Gene
- [This gene may play a role in cell differentiation. ( NCI )] (UMLS (NCI) C1424621) LRRC17;
LRRC17 Gene =Gene or Genome | - 46. leukocyte proliferation
- [ ] (UMLS (CSP) C0598773) =Cell Function
|
- 3. Leucine Rich Repeat Neuronal 5 Gene
- [This gene plays a role in cell adhesion and signal transduction. ( NCI )] (UMLS (NCI) C1424631) LRRN5;
LRRN5 Gene =Gene or Genome | - 47. Leukocyte Therapy
- (UMLS (NCI) C0281179) =Therapeutic or Preventive Procedure
|
- 4. leucine zipper
- [Domains in DNA-binding proteins that contain amino acid sequences that show periodic arrays of leucine residues. These residues exist in an alpha-helical conformation, with the leucine side chains extending from one alpha helix interdigitating with those displayed from a similar alpha helix of a second polypeptide, facilitating dimerization. ( NCI )] (UMLS (CSP) C0079686) =Molecular Function; Spatial Concept ;
| - 48. Leukocyte Trafficking
- [The circulation of white blood cells from the blood stream to tissues or secondary lymphoid organs, to the lymphatics, and back to the bloodstream via the thoracic duct. ( NCI )] (UMLS (NCI) C1326500) =Cell Function
|
- 5. Leucine-Rich, Glioma Inactivated 1 Gene
- [This gene plays a role in neural cell function and is involved in the suppression of brain cancer. ( NCI )] (UMLS (NCI) C1367458) LGI1;
LGI1 Gene =Gene or Genome | - 49. leukocyte transformation
- [ ] (UMLS (CSP) C0920709) =Cell Function ;
|
- 6. LEUCOCORIA
- [ ] (UMLS (ICD9CM) C0152458) =Disease or Syndrome
| - 50. leukocyte transfusion
- [transfer of leukocytes from a donor to a recipient or reinfusion to the donor. ( CSP )] (UMLS (CSP) C0086548) =Therapeutic or Preventive Procedure ;
=blood transfusion;
|
- 7. leucosarcoma
- [ ] (UMLS (CSP) C0023535) =Neoplastic Process ;
| - 51. Leukocyte Tyrosine Kinase Gene
- [This gene plays a role in leukocyte tyrosine kinase signal transduction and diverse cellular regulatory pathways. ( NCI )] (UMLS (NCI) C1334352) LTK;
LTK Gene =Gene or Genome ;
|
- 8. Leucovorin Calcium/Mercaptopurine/Methotrexate/Prednisolone
- (UMLS (NCI) C0935841) =Therapeutic or Preventive Procedure
| - 52. Leukocytes
- (UMLS (HL7) C1547962) =Intellectual Product =Specimen Source Codes;
|
- 9. Leucovorin Calcium/Mercaptopurine/Methotrexate/Prednisolone/Vincristine
- (UMLS (NCI) C0935837) =Therapeutic or Preventive Procedure
| - 53. Leukocytes
- (UMLS (HL7) C1550647) =Body Substance =SpecimenEntityType;
|
- 10. Leucovorin Calcium/Mercaptopurine/Methotrexate/Vincristine
- (UMLS (NCI) C1327985) =Therapeutic or Preventive Procedure ;
| - 54. Leukocytic Cast Formation
- (UMLS (NCI) C1334393) =Finding; ;
|
- 11. Leucovorin Calcium/Methotrexate
- (UMLS (NCI) C0879552) =Therapeutic or Preventive Procedure
| - 55. LEUKOCYTOPENIA NOS
- [reduction in the number of leukocytes in the blood, the count being 5000 per cubic millimeter or less. ( CSP )] (UMLS (ICD9CM) C0023530) =Disease or Syndrome ;
=Diseases of white blood cells;
=agranulocytosis;
LYMPHOCYTOPENIA;
agranulocytosis;
LYMPHOCYTOPENIA;
|
- 12. leukapheresis
- [selective separation and removal of leukocytes from withdrawn blood, the remainder of the blood then being retransfused into the donor. ( CSP )] (UMLS (NCI) C0023416) =Therapeutic or Preventive Procedure =blood treatment;
| - 56. leukocytosis
- [transient increase in the number of leukocytes in a body fluid. ( CSP )] (UMLS (CSP) C0023518) =Pathologic Function ;
=Diseases of white blood cells;
Pathologic Process =lymphocytosis;
Leukemoid reaction;
lymphocytosis |
- 13. LEUKASE
- [A quantitative measurement of the amount of leukocyte esterase present in a sample. ( NCI )] (UMLS (NCI) C0427760) =Laboratory Procedure
| - 57. LEUKODYSTROPHY
- [group of diseases affecting the white matter of the brain, especially the cerebral hemispheres, due to defects in the formation and maintenance of myelin in infants and children. ( CSP )] (UMLS (ICD9CM) C0023520) =Disease or Syndrome ;
=CEREB DEGENERATION NOS;
=beta galactocerebrosidase deficiency;
arylsulfatase A deficiency;
adrenoleukodystrophy |
- 14. Leukemia
- [progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow; classified according to degree of cell differentiation as acute or chronic, and according to predominant type of cell involved as myelogenous or lymphocytic.(CSP)] (UMLS (ICPC) C0023418) (Leukemia; LEUZEMIA; Leukaemi; Leukemie; LEUKEMIA; Leucemie; Leukaemie; (108); leukaemia; Leucemia; LEUKEMI; Leucemia; Leucemia; LEUKEMI) Leukemia =Neoplastic Process ;
=Neoplasms by Histologic Type; blood/lymphatic cancer; BLOOD, BLOOD FORMING ORGANS, LYMPHATICS, SPLEEN; Diagnosis/Diseases Component =Acute Erythroblastic Leukemia; Leukemia, Lymphocytic; acute monoblastic leukemia; granulocytic leukemia; Leukemia Plasmacytic; Leukemia, Radiation-Induced; Acute Leukemia; mouse leukemia; viral leukemia; chronic leukemia; Leukemia, Experimental; hairy cell leukemia; Leukemia, Lymphocytic; granulocytic leukemia; Leukemia Plasmacytic; Leukemia, Radiation-Induced; Leukemia, Subleukemic; Leukemia, Feline; Enzootic Bovine Leukosis; | - 58. Leukoencephalopathy
- [White matter changes first described in children with leukemia, associated with radiation and chemotherapy injury, often associated with methotrexate; pathologically characterised by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation. ( NCI )] (UMLS (NCI) C0270612) =Disease or Syndrome
|
- 15. Leukemia (in Remission)
- [History of leukemia after therapy with no evidence on the peripheral blood or bone marrow of leukemia (normalization of all hematologic parameters). ( NCI )] (UMLS (NCI) C0686584) =Neoplastic Process
| - 59. Leukokeratosis of Oral Mucosa
- [white patch seen on the oral mucosa; considered a premalignant condition and is often tobacco-induced. ( CSP )] (UMLS (NCI) C0023532) =Neoplastic Process ;
=Keratotic Plaque;
Lip and Oral Cavity Neoplasm;
oral pharyngeal hyperplasia;
=Hairy Leukoplakia of Mouth |
- 16. leukemia inhibitory factor
- [affects many systems, including hematopoietic, embryonic, bone, hepatic, neuronal, and fat tissues. ( CSP )] (UMLS (CSP) C0125606) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
=Cytokine;
| - 60. Leukoplakia of Buccal Mucosa
- (UMLS (NCI) C0399470) =Neoplastic Process
|
- 17. Leukemia Inhibitory Factor (Cholinergic Differentiation Factor) Gene
- [This gene is involved in macrophage differentiation. ( NCI )] (UMLS (NCI) C1366463) LIF;
LIF Gene =Gene or Genome | - 61. Leukoplakia of Lips
- (UMLS (NCI) C0399602) =Neoplastic Process
|
- 18. Leukemia Inhibitory Factor Receptor
- [Leukemia Inhibitory Factor (LIF), encoded by the LIF gene, is a polyfunctional cytokine that affects the differentiation, survival, and proliferation of a wide variety of cells in the adult and the embryo. LIF action is mediated through a high-affinity receptor complex composed of Leukemia Inhibitory Factor Receptor (a low-affinity LIF binding chain) and gp130 (a high-affinity converter subunit). The high-affinity complex also binds oncostatin M, a related cytokine. Both Leukemia Inhibitory Factor Receptor and gp130 are members of a family of cytokine receptors that includes components of the receptors for the majority of hematopoietic cytokines and for cytokines that affect other systems, including the ciliary neurotrophic factor, growth hormone and prolactin. (from OMIM) ( NCI )] (UMLS (NCI) C0125607) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor
| - 62. Leukoplakia of oral mucosa, including tongue
- [ ] (UMLS (ICD9CM) C1112530) LEUKOPLAKIA ORAL MUCOSA =Disease or Syndrome ;
|
- 19. Leukemia Inhibitory Factor Receptor Gene
- [This gene plays a critical role in cell fate and proliferation in both embryonic and adult cells. ( NCI )] (UMLS (NCI) C1334339) LIFR;
LIFR Gene;
=Gene or Genome ;
| - 63. Leukoplakia of the Vagina
- (UMLS (NCI) C0156385) =Neoplastic Process
|
- 20. Leukemia of unspecified cell type, subacute
- (UMLS (ICD9CM) C0153924) =Neoplastic Process
| - 64. Leukoplakia of Tongue
- (UMLS (NCI) C0241435) =Neoplastic Process
|
- 21. Leukemia Peptide Vaccine, PR1
- [A synthetic HLA-A2-restricted nonapeptide derived from proteinase 3 with potential use in cancer immunotherapy. Cytotoxic T lymphocytes (CTL) primed with proteinase 3 PR1 peptide attack leukemic cells that express proteinase 3 aberrantly. Proteinase 3 is a serine proteinase that activates progelatinase A and is involved in metastasis and angiogenesis. (NCI04) ( NCI )] (UMLS (NCI) C0879440) PR1 Leukemia Peptide Vaccine;
Proteinase 3:PR1 Peptide;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 65. leukopoiesis
- [forming and production of leukocytes. ( CSP )] (UMLS (CSP) C0525007) =Organ or Tissue Function ;
=hematopoiesis;
|
- 22. Leukemia Plasmacytic
- [rare type of acute leukemia in which the predominating cell in the peripheral blood is the plasma cell; it is often seen in conjunction with multiple myeloma and may be a variant form of that disease. ( CSP )] (UMLS (NCI) C0023484) =Neoplastic Process =Blood (Leukemia);
Lymphoproliferative Disorder;
plasma cell neoplasm;
| - 66. leukopoietic factor
- [ ] (UMLS (CSP) C0596833) =Organic Chemical =hematopoietic growth factor;
=Thymopoietin;
thymosin;
|
- 23. Leukemia Plasmacytic (in Remission)
- [History of plasmacytic leukemia after therapy with no evidence on the peripheral blood or bone marrow of leukemia (normalization of all hematologic parameters). ( NCI )] (UMLS (NCI) C0153871) =Neoplastic Process
| - 67. Leukoreduced
- (UMLS (HL7) C1548981) =Idea or Concept =Blood Product Processing Requirements;
|
- 24. Leukemia Stem Cell
- [A leukemia originating from a precursor bone marrow cell which is in an earlier developmental stage compared to lymphoblasts and myeloblasts. — 2003 ( NCI )] (UMLS (NCI) C1378511) Stem Cell Leukemia =Neoplastic Process
| - 68. Leukoreduced Platelet Pheresis
- (UMLS (HL7) C1547255) =Intellectual Product =Blood Product Code;
|
- 25. leukemia virus
- [not a taxonomical name; concept term for when any leukemia viruses are studied, or for when the specific virus is not mentioned; a virus causing malignant disease of the blood forming organs. ( CSP )] (UMLS (CSP) C0596828) =Virus =oncogenic virus;
| - 69. Leukoregulin
- [Secreted by activated natural killer lymphocytes as a 50-kDa glycoprotein lymphokine, Leukoregulin can up regulate the expression of hyaluronan and prostaglandin-endoperoxide H synthase 2 (PTGS2), the inflammatory cyclooxygenase. Leukoregulin shows tumor growth inhibitory activity, enhances membrane permeability, and promotes the uptake of cytotoxic drugs by tumors cells without affecting these processes in normal cells. (NCI) ( NCI )] (UMLS (NCI) C0064839) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
|
- 26. Leukemic Lymphoma
- [A usually terminal event in the clinical course of lymphomas. The term indicates the presence of atypical, clonal (malignant) lymphocytes (lymphoma cells) in the peripheral blood. —2003 ( NCI )] (UMLS (NCI) C0852709) Leukemic Phase of Lymphoma;
Leukemic Phase of Non-Hodgkin Lymphoma;
Leukemic Phase of Non-Hodgkin's Lymphoma;
=Neoplastic Process | - 70. Leukorrhea
- [A clear or white discharge from the VAGINA, consisting mainly of MUCUS. ( MSH )] (UMLS (NCI) C0023533) =Disease or Syndrome ;
=Discharge, vaginal;
|
- 27. Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites
- [ ] (UMLS (ICD9CM) C0375091) =Neoplastic Process
| - 71. Leukorrhea, not specified as infective
- (UMLS (ICD9CM) C0023534) =Disease or Syndrome ;
|
- 28. leukemogenesis
- [The causation (or induction), development, and progression of a leukaemic disease. ( NCI )] (UMLS (CSP) C0598766) =Neoplastic Process
| - 72. Leukostasis
- [A disorder involving the aberrant infiltration and aggregation of leukocytes into the vasculature of the body. Leukostasis is typically detected in the brain and lungs of persons with leukemia. It requires substantial ablative modalities to both reduce the number of cells present and to ensure dispersion of the aggregates. ( NCI )] (UMLS (NCI) C0282548) =Disease or Syndrome ;
=Diseases of white blood cells;
|
- 29. Leukemoid reaction
- [A peripheral blood picture resembling that of leukemia or indistinguishable from it on the basis of morphologic appearance alone. (Dorland, 27th ed) ( MSH )] (UMLS (ICD9CM) C0023501) =Disease or Syndrome =leukocytosis;
MPD | - 73. leukotaxic factor
- [ ] (UMLS (CSP) C0598143) =Biologically Active Substance ;
|
- 30. Leukeran
- (UMLS (NCI) C0699996) =Organic Chemical; Pharmacologic Substance; Hazardous or Poisonous Substance
| - 74. leukotomy
- [ ] (UMLS (CSP) C0023537) =Therapeutic or Preventive Procedure ;
|
- 31. Leukerin
- (UMLS (NCI) C0729099) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 75. leukotoxin
- [ ] (UMLS (CSP) C0064841) =Pharmacologic Substance; Biologically Active Substance; Hazardous or Poisonous Substance
|
- 32. leukocyte
- [white blood cell, specifically a colorless cell with a nucleus, found in blood and lymph; leukocytes are capable of amoeboid movement; they can produce antibodies and move through the walls of vessels to migrate to sites of injury, where they isolate and destroy dead tissue, foreign protein and bacteria. ( CSP )] (UMLS (CSP) C0023516) =Cell =blood cell;
allergic/immunologic body system;
Body Part;
Unclassified Ingredients =Granulocyte;
K cell;
lymphocyte;
Monocyte;
amebocyte;
LEUKOCYTES TEST;
| - 76. Leukotriene
- [family of biologically active compounds derived from arachidonic acid by oxidative metabolism through the 5-lipoxygenase pathway; participate in host defense reactions and pathophysiological conditions such as immediate hypersensitivity and inflammation; have potent actions on many essential organs and systems, including the cardiovascular, pulmonary, and central nervous system as well as the gastrointestinal tract and the immune system. ( CSP )] (UMLS (NCI) C0023545) =Eicosanoid; Biologically Active Substance =eicosanoid;
=arachidonate |
- 33. leukocyte activation disorder
- [condition in which there is a deviation from or interruption of the normal stimulation of leukocytes by specific antigens or nonspecific mitogens resulting in a lack of or limited production of cytokines. ( CSP )] (UMLS (CSP) C0596830) =Pathologic Function =Diseases of white blood cells;
| - 77. Leukotriene B4
- [The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) ( MSH )] (UMLS (NCI) C0023546) =Eicosanoid; Biologically Active Substance
|
- 34. leukocyte activation/transformation
- [stimulation of leukocytes by specific antigens or nonspecific mitogens resulting in macromolecular synthesis and production of cytokines; followed by proliferation and differentiation of the progeny into various effector and memory cells. ( CSP )] (UMLS (CSP) C0596829) =Cell Function =Cell Mediated Immunity;
antigen presentation | - 78. Leukotriene B4 Receptor Gene
- [This gene is in involved in G protein-coupled receptor signal transduction and chemotaxis. ( NCI )] (UMLS (NCI) C1334350) LTB4R;
LTB4R Gene =Gene or Genome ;
|
- 35. Leukocyte Adhesion Deficiency
- (UMLS (NCI) C0272187) =Disease or Syndrome
| - 79. leukotriene receptor
- [Cell-surface receptors that bind LEUKOTRIENES with high affinity and trigger intracellular changes influencing the behavior of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes LTB4; LTC4; LTD4; and LTE4. ( MSH )] (UMLS (CSP) C0206517) =Amino Acid, Peptide, or Protein; Receptor
|
- 36. leukocyte adhesion molecule
- [receptors on leukocytes or target tissues that mediate leukocyte- target cell adhesion and, in conjunction with antigen binding to the T cell receptor, lymphocyte activation. ( CSP )] (UMLS (CSP) C0034822) =Amino Acid, Peptide, or Protein; Immunologic Factor; Receptor =Cell Surface Antigens;
Adhesion Molecule;
Receptor;
| - 80. leukovirus
- [ ] (UMLS (CSP) C0006562) =Virus
|
- 37. leukocyte antigen 1
- [ ] (UMLS (CSP) C0598074) =Amino Acid, Peptide, or Protein; Immunologic Factor
| - 81. LeuLeuOMe
- [A 2-amino acid compound with immunomodulatory activity. L-leucyl-L-leucine methyl ester (LLME) is a lysosomotropic agent entering cells via receptor-mediated endocytosis. LLME undergoes condensation process catalyzed by dipeptidyl peptidase I (DPPI) in lysosomes. Condensation of LLME leads to lysosomal rupture and DNA fragmentation in DPPI-expressing immune cells such as cytotoxic T-cells and natural killer cells. Therefore, this agent maybe able to decrease the incidence of graft versus host disease (GVHD) via cytotoxic T-cell depletion. Furthermore, LLME has the potential in augmenting antibody production when used in pretreatment of peripheral blood mononuclear cells (PBMCs), possibly via interfering gene expressions of inflammatory factors. ( NCI )] (UMLS (NCI) C0281255) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
|
- 38. leukocyte antigen typing
- [test to detect genetic markers on white blood cells. ( CSP )] (UMLS (CSP) C0596831) =Laboratory Procedure =histocompatibility typing;
| - 82. LEUP/SUR
- (UMLS (NCI) C0281358) =Therapeutic or Preventive Procedure
|
- 39. leukocyte count
- [number of white blood cells per unit volume in venous blood. ( CSP )] (UMLS (CSP) C0023508) =Laboratory Procedure =blood cell count;
| - 83. LEUP/TMX
- (UMLS (NCI) C0281620) =Therapeutic or Preventive Procedure
|
- 40. leukocyte depletion therapy
- [immunosuppression by reduction of leukocytes. ( CSP )] (UMLS (CSP) C0596832) =Therapeutic or Preventive Procedure =blood cell depletion therapy;
| - 84. leupaxin
- [ ] (UMLS (CSP) C0674896) =Amino Acid, Peptide, or Protein
|
- 41. leukocyte elastase
- [An enzyme that catalyzes the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of Ala and Val, with greater specificity for Ala. EC 3.4.21.37. ( MSH )] (UMLS (CSP) C0064833) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 85. Leupurin
- (UMLS (NCI) C0729100) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 42. leukocyte homing
- [ ] (UMLS (CSP) C1328922) =Cell Function; ;
| - 86. Leurocristine Sulfate
- [The sulfate salt of a naturally occurring vinca alkaloid. Vincristine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04) ( NCI )] (UMLS (NCI) C0042680) =Organic Chemical; Pharmacologic Substance ;
=22-Oxovincaleukoblastine;
=VINCRISTINE SULFATE 1 MG/ML |
- 43. leukocyte mediator
- [ ] (UMLS (CSP) C1328923) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
| - 87. Leustatin
- (UMLS (NCI) C0701346) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
|
- 44. leukocyte oxidative burst
- [large increase in oxygen uptake by neutrophils and most types of tissue macrophages through activation of an NADPH/cytochrome b-dependent oxidase that reduces oxygen to a superoxide. ( CSP )] (UMLS (CSP) C0085416) =Cell Function ;
=bactericidal immunity;
| - 88. leuvectin
- [An agent that delivers the gene for interleukin-2 (IL-2) into cells to increase production of IL-2 by the cells. ( NCI )] (UMLS (NCI) C0677671) =Organic Chemical; Pharmacologic Substance ;
|
home
